BiotechTube

Testosterone Enanthate + Finasteride

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Male Hypogonadism

Conditions

Male Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy

Trial Timeline

Jan 1, 2007 → Oct 1, 2014

NCT ID
NCT00475501

About Testosterone Enanthate + Finasteride

Testosterone Enanthate + Finasteride is a phase 2 stage product being developed by Merck for Male Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT00475501. Target conditions include Male Hypogonadism, Muscle Atrophy, Sarcopenia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00475501Phase 2Completed

Competing Products

20 competing products in Male Hypogonadism

See all competitors
ProductCompanyStageHype Score
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
33
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
77
[14C]-LY3549492 + LY3549492 + [14C]-LY3549492Eli LillyPhase 1
33
CT-P41 + EU-approved ProliaCelltrionPhase 1
33
CT-P55 + US-licensed Cosentyx + EU-approved CosentyxCelltrionPhase 1
33
CT-P52CelltrionPhase 1
33
CT-P43 + CT-P43CelltrionPhase 1
33
Telmisartan + Amlodipine + RosuvastatinYuhanPhase 1
33
ASP3325 + PlaceboAstellas PharmaPhase 1
33
TRK-100STPAstellas PharmaPhase 1
33
EnsitrelvirShionogiPhase 1
33
E6011 + E6011 Matching PlaceboEisaiPhase 1
33
E6130 + PlaceboEisaiPhase 1
33
Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
85
E3112EisaiPhase 1
33
E2022 Tape FormulationEisaiPhase 1
33
Placebo + E3112EisaiPhase 1
33
[14C]-E6007EisaiPhase 1
33
E2022 + E2022 + E2022 + E2022 + E2022EisaiPhase 1
33

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85